Evidence map›Paper›PMID 41023116›Full record

ArticleScientific reports2025

Assessment of brain penetration and tumor accumulation of niraparib and olaparib: insights from multimodal imaging in preclinical models.

M Reid Groseclose, Jeremy A Barry, Tina Skedzielewski, Yongle Pang, Yinghe Li, Gerald McDermott, Jennifer Deutsch, Chakravarthi Balabhadrapatruni, William Benson, David Lim and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Current and emerging therapies in IDH-mutant glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

M Reid Groseclose *Bioimaging, GSK, Collegeville, PA, USA. reid.x.groseclose@gsk.com.
Jeremy A Barry *Bioimaging, GSK, Collegeville, PA, USA.
Tina SkedzielewskiBioimaging, GSK, Collegeville, PA, USA.
Yongle PangDMPK, GSK, Collegeville, PA, USA.
Yinghe LiDMPK, GSK, Collegeville, PA, USA.
Gerald McDermottLaboratory Animal Sciences and Governance, GSK, Collegeville, PA, USA.
Jennifer DeutschLaboratory Animal Sciences and Governance, GSK, Collegeville, PA, USA.
Chakravarthi BalabhadrapatruniOncology Research Unit, GSK, Collegeville, PA, USA.
William BensonBioimaging, GSK, Collegeville, PA, USA.
David LimResearch Statistics, Biostatistics, GSK, Collegeville, PA, USA.
Hoang TranResearch Statistics, Biostatistics, GSK, Collegeville, PA, USA.
Elisabeth MinthornDMPK, GSK, Collegeville, PA, USA.
Casey KmettDMPK, GSK, Collegeville, PA, USA.
Theresa RoethkeDMPK, GSK, Collegeville, PA, USA.
Shannon BerryDMPK, GSK, Collegeville, PA, USA.
Elaina McCormickDMPK, GSK, Collegeville, PA, USA.
William FeeneyLaboratory Animal Sciences and Governance, GSK, Collegeville, PA, USA.
M A RingenbergNonclinical Safety, GSK, Collegeville, PA, USA.
Sean MaguireLaboratory Animal Sciences and Governance, GSK, Collegeville, PA, USA.
Geeta SharmaOncology Research Unit, GSK, Collegeville, PA, USA.
Amine AziezGlobal Medical Affairs Oncology, GSK, Zug, Switzerland.
Elaine M PaulOncology Medicine Development, GSK, Collegeville, PA, USA.
Kunal TaskarDMPK, GSK, Collegeville, PA, USA.
Keyur GadaDMPK, GSK, Collegeville, PA, USA.
Hasan AlsaidBioimaging, GSK, Collegeville, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most significant challenges in developing new treatments for primary and metastatic brain tumors is the requirement for crossing the blood-brain barrier (BBB). By examining the brain penetration and spatial distribution of drug candidates in animal models, we can gain valuable insights into their potential for clinical success. In this study, we used multimodal imaging alongside complementary analytical methods to assess the brain distribution of two clinically advanced poly(ADP-ribose) polymerase (PARP) inhibitors-niraparib and olaparib-across three preclinical models: healthy brain (nonhuman primates (NHPs)), primary brain tumors (mouse glioblastoma), and metastatic brain tumors (mouse breast cancer metastasis). The results suggest that niraparib has a superior ability (relative to olaparib) to penetrate the BBB, distribute widely throughout the brain, and accumulate in brain tumor lesions. These findings support further studies of niraparib as a potential treatment for tumors in the human brain.

Indexed as

BrainBrain NeoplasmsIndazolesPhthalazinesPiperazinesPiperidinesPoly(ADP-ribose) Polymerase InhibitorsAnimalsBlood-Brain BarrierCell Line, TumorDisease Models, AnimalFemaleGlioblastomaHumansMiceMultimodal ImagingIndazolesniraparibolaparibPhthalazinesPiperazinesPiperidinesPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID41023116
PMCPMC12480552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.